Zacks: Analysts Expect Agile Therapeutics Inc (AGRX) Will Post Earnings of -$0.11 Per Share

Share on StockTwits

Wall Street brokerages expect that Agile Therapeutics Inc (NASDAQ:AGRX) will post ($0.11) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.10). Agile Therapeutics posted earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year over year growth rate of 47.6%. The business is scheduled to issue its next quarterly earnings report on Monday, May 6th.

According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.46) per share for the current fiscal year, with EPS estimates ranging from ($0.64) to ($0.34). For the next financial year, analysts forecast that the business will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.76) to $0.11. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04.

A number of research analysts have issued reports on the stock. Maxim Group restated a “buy” rating and issued a $3.00 target price on shares of Agile Therapeutics in a report on Monday, February 11th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Agile Therapeutics in a research note on Friday, January 11th. Finally, ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 11th.

Agile Therapeutics stock traded down $0.01 during midday trading on Tuesday, hitting $1.59. 5,065 shares of the stock were exchanged, compared to its average volume of 931,422. Agile Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $3.17. The stock has a market cap of $69.14 million, a P/E ratio of -2.74 and a beta of 0.36.

Institutional investors and hedge funds have recently modified their holdings of the stock. Fosun International Ltd acquired a new stake in shares of Agile Therapeutics during the 3rd quarter valued at about $180,000. Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 54.3% during the 3rd quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 260.7% during the 4th quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Agile Therapeutics by 24.0% during the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after buying an additional 18,038 shares during the last quarter. 27.42% of the stock is currently owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: Buy-Side Analysts

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.